Who may be eligible for satri-cel CAR-T therapy in China?

Satri-cel is approved in China for patients with Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma whose disease has progressed after at least two prior lines of treatment. Individual eligibility requires a specialist assessment of the patient's complete medical history, pathology, biomarkers, and current condition.

How much does satri-cel CAR-T treatment cost in China?

The published price of the satri-cel treatment itself is RMB 990,000 per patient dose. The total cost of receiving treatment in China can be higher once specialist assessment, testing, hospitalization, supportive care, travel, accommodation, and follow-up are included. ChinaCureLink can arrange a case-specific cost assessment after medical records have been reviewed.

Can I return to my home country after CAR-T treatment in China?

Yes. International patients can return home after completing the appropriate treatment and immediate monitoring period, with continued follow-up coordinated between the Chinese treatment team and their doctors at home. The exact timing depends on the individual patient's condition and the treating team's assessment.

top of page

ChinaCurelink
a MedeboundHEALTH Company

FREE CONSULTATION

9,000 Kilometres: How a New Zealand Patient Became the First International Patient to Complete Solid-Tumor CAR-T Treatment in China

ChinaCureLink

Fri Sep 11 2026

7 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page